OTC Markets Stock News
All posts tagged "COVID-19"
-
1.3KBiotechCytoDyn (CYDY) at Crossroads: Past and Current Leadership Collide in Epic Grudgematch
Latest 8-K filing settles dispute for $7.6 million but paves way for Pestell share repurchase at par 13-D Group is outspoken but...
-
2.4K1BiotechCytoDyn’s Smoking Gun For an Immediate EUA
The controversy surrounding CytoDyn Inc. (OTCMKTS: CYDY) stock is startling. An aggressive pack of short sellers claim its leronlimab Covid trial didn’t...
-
2.5KMomentum & GrowthLow Floater Boon Industries (OTCMKTS: BNOW) Breaks Silence with Mega Projections and COVID-19 Product Launch
Boon Industries (OTCMKTS: BNOW) has been quiet for the past year and finally broke its silence with an update letter from its...
-
13.5KBiotechRISE of the COVID-19 Therapeutics CytoDyn (OTCMKTS: CYDY) & Humanigen (NASDAQ:HGEN)
Enrollment Key Metric in Therapeutic Race Philippines EUA Relevant to CytoDyn, not Humanigen Highly Credentialed Humanigen Team Possibility of NASDAQ Uplisting for...
-
33.4KBiotechWhy RLFTF Stock Is The Best COVID-19 Bet
Right now a lot of traders and investors are asking what the next move to make in regards to COVID-19 plays. Many...
-
14.1KBiotechTonix Pharmaceuticals: A Bull Run Is Coming
Tonix Pharmaceuticals is a name that we covered last month before its run to $2.50, which you can read here. What attracted...
-
10.7KBiotechVBI Vaccines Stock Destined For New Highs
VBI Vaccines stock has dropped along with the other COVID-19 vaccine players after Russia announced it developed a coronavirus vaccine. Like many...
-
17.2K2BiotechWading through the STAT News FUD Attack on CytoDyn Inc. (OTCMKTS: CYDY)
CytoDyn Inc. (OTCMKTS: CYDY) announced superb top-line data in their mild to moderate COVID-19 phase 2 trial and did not disappoint; however,...
-
19.4KBiotechTNXP Stock: A Top COVID-19 Vaccine Play
There’s no denying the best sector for investors right now is the COVID-19 vaccine plays. We at Insider Financial have nailed quite...
-
31.2K1BiotechCytoDyn’s (OTCMKTS: CYDY) Strong Safety Data in Mild to Moderate Smokes Gilead (NASDAQ: GILD) & Crushes Endpoint Leading to the First Potential COVID-19 Approval
CytoDyn Inc. (OTCMKTS: CYDY) announced groundbreaking safety results from its phase 2 Mild to Moderate COVID-19 trial today. The company reported a...
